Enliven insider plans Rule 144 sale of 1,230 shares

Enliven Therapeutics insider Richard Heyman filed a notice of proposed sale under Rule 144 covering up to 1,230 shares of common stock.

Rhea-AI Filing Summary

Enliven Therapeutics insider Richard Heyman filed a notice of proposed sale under Rule 144 covering up to 1,230 shares of common stock. The planned sale through Jefferies LLC on the Nasdaq has an aggregate market value of $32,865.60, with 59,000,000 shares outstanding. The approximate sale date indicated is February 17, 2026. In the past three months, Heyman has sold Enliven securities in three transactions totaling 8,015 shares for $200,655.12, 4,285 shares for $107,125.60, and 1,230 shares for $32,901.55.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Enliven Therapeutics (ELVN) disclose?

The filing discloses that Richard Heyman intends to sell up to 1,230 Enliven Therapeutics common shares under Rule 144. The proposed sale, routed through Jefferies LLC on Nasdaq, has an indicated aggregate market value of $32,865.60, based on the figures shown.

How many Enliven Therapeutics (ELVN) shares are proposed to be sold?

The notice covers a proposed sale of 1,230 Enliven Therapeutics common shares. These shares were originally acquired on January 25, 2020 as “Founders Shares” from Enliven Therapeutics, with the same date listed for acquisition and payment in the filing.

What is the market value of the Enliven (ELVN) shares in the Form 144?

The Form 144 shows an aggregate market value of $32,865.60 for the 1,230 Enliven Therapeutics shares to be sold. This value is based on the information in the securities information table associated with the planned Nasdaq sale through Jefferies LLC.

How many Enliven Therapeutics (ELVN) shares are outstanding in this filing?

The filing states that 59,000,000 Enliven Therapeutics common shares are outstanding. This figure appears in the securities information section alongside the 1,230 shares proposed for sale and serves as a baseline context for the company’s total share count.

When is the proposed Enliven (ELVN) Rule 144 sale expected to occur?

The approximate date of sale listed is February 17, 2026. This date appears in the securities information table describing the 1,230 Enliven Therapeutics common shares to be sold on Nasdaq through Jefferies LLC, subject to market conditions and Rule 144 requirements.

What Enliven Therapeutics (ELVN) insider trading activity occurred in the last 3 months?

The filing lists three prior sales by Richard Heyman over the last three months: 8,015 securities for $200,655.12, 4,285 for $107,125.60, and 1,230 for $32,901.55. All transactions are tied to Enliven Therapeutics securities according to the table provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 04:44 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001584759
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Enliven Therapeutics, Inc.
SEC File Number	001-39247
Address of Issuer	6200 LOOKOUT ROAD BOULDER COLORADO 80301
Phone	720-647-8519
Name of Person for Whose Account the Securities are To Be Sold	Heyman Richard A.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	1230	32865.60	59000000	02/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/25/2020	Founders Shares	Enliven Therapeutics			1230	01/25/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Richard Heyman 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/08/2026	8015	200655.12
Richard Heyman 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/09/2026	4285	107125.60
Richard Heyman 6200 Lookout Road 1st Fl Boulder CO 80301	Enliven Therapeutics	01/20/2026	1230	32901.55

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 11/15/2024, and all representations regarding material non-public information were made as of the adoption of the plan. The shares in this filing will be sold from The Richard A Heyman and Anne E Daigle Trust UAD 01/01/95.
Date of Notice	02/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Richard Heyman
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)